Número 1 - EII al dÃa
Número 1 - EII al dÃa
Número 1 - EII al dÃa
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Debate<br />
gicas en la EC, la eficacia, seguridad y costes de las distintas<br />
<strong>al</strong>ternativas terapéuticas para la inducción/mantenimiento<br />
de remisión en la EC. Asimismo, es importante<br />
establecer el significado de “modificación de la<br />
historia natur<strong>al</strong> de la enfermedad” y demostrar si re<strong>al</strong>mente<br />
las distintas aproximaciones terapéuticas son<br />
capaces de modificarla. Por otro lado, deben loc<strong>al</strong>izarse<br />
y agruparse las distintas mutaciones genéticas asociadas<br />
a la EC y establecer su función, comprender el<br />
impacto ambient<strong>al</strong> sobre la expresión fenotípica de la<br />
enfermedad y reconocer factores genéticos, farmacogenéticos,<br />
fenotípicos y biológicos que permitan predecir<br />
el curso evolutivo y la respuesta terapéutica de<br />
los pacientes con EC para identificar a aquellos subgrupos<br />
que verdaderamente puedan beneficiarse del<br />
uso más precoz de terapias más agresivas. Hasta entonces,<br />
los datos científicos de los que disponemos son<br />
insuficientes para tratar desde el diagnóstico de EC, a<br />
todos nuestros pacientes, con inmunomoduladores y<br />
terapias biológicas.<br />
BIBLIOGRAFÍA<br />
1. Hanauer SB, Meyers S. Management of Crohn’s disease in adults. Am J<br />
Gastroenterol 1997;92:204-11.<br />
2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S,<br />
Colombel JF, et <strong>al</strong>. Maintenance infliximab for Crohn’s disease: the<br />
ACCENT I randomised tri<strong>al</strong>. Lancet 2002;359:1541-9.<br />
3. Sands BE, Anderson FH, Bernstein CN, Chein WY, Feagan BG, Fedorak<br />
RN, et <strong>al</strong>. Infliximab maintenance therpy for fistulizing Crohn’s disease. N<br />
Engl J Med 2004;350:876-85.<br />
4. D’Haens G, Van Deventer S, Van Hogezand R, Ch<strong>al</strong>mers D, Kothe C,<br />
Baert F, et <strong>al</strong>. Endoscopic and histologic<strong>al</strong> he<strong>al</strong>ing with infliximab antitumor<br />
necrosis factor antibodies in Crohn’s disease: A European multicenter<br />
tri<strong>al</strong>. Gastroenterology 1999;116:1029-34.<br />
5. Best WR, Beckel JM, Singleton JW, Kern Fjr. Development of a Crohn’s<br />
disease activity index. Nation<strong>al</strong> Cooperative Crohn’s Disease Study.<br />
Gastroenterology 1976;70:439-444.<br />
6. Mary JY, Modigliani R. Development and v<strong>al</strong>idation of an endoscopic<br />
index of the severity for Crohn’s disease: a prospective multicentre study.<br />
Groupe d’Etudes Therapeutiques des affections Inflammatoires de Tube<br />
Digestif (GETAID). Gut 1989;30:983-989.<br />
7. Freeman HJ. Natur<strong>al</strong> history and clinic<strong>al</strong> behavior of Crohn’s disease<br />
extending beyond two decades. J Clin Gastroenterol 2003;37:216-9.<br />
8. Fedorak RN. Is it time to re-classify Crohn’s disease?. Best Pract Res Clin<br />
Gastroenterol 2004;18l:99-106.<br />
9. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et <strong>al</strong>.<br />
Nation<strong>al</strong> Cooperative Crohn’s Disease Study: results of drug treatment.<br />
Gastroenterology 1979;77:847-69.<br />
10. M<strong>al</strong>chow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et <strong>al</strong>.<br />
European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment.<br />
Gastroenterology 1984;86:249-66.<br />
11. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG,<br />
Wruble LD, et <strong>al</strong>. Mes<strong>al</strong>amine capsules for the treatment of active Crohn’s<br />
disease: results of a 16-week tri<strong>al</strong>. Pentasa Crohn’s Disease Study Group.<br />
Gastroenterology 1993;104:1293-301.<br />
12. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized,<br />
double-blind, placebo-controlled tri<strong>al</strong> of the or<strong>al</strong> mes<strong>al</strong>amine (5-<br />
ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis<br />
and ileocolitis. J Clin Gastroenterol 1994;19:278-82..<br />
13. Prantera C, Cottone M, P<strong>al</strong>lone F, Annese V, Franze A, Cerutti R, et <strong>al</strong>.<br />
Mes<strong>al</strong>amine in the treatment of mild to moderate active Crohn’s ileitis:<br />
results of a randomized, multicenter tri<strong>al</strong>. Gastroenterology 1999;<br />
116:521-6.<br />
14. Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, et <strong>al</strong>. A<br />
comparative study of metronidazole and sulfas<strong>al</strong>azine for active crohn’s<br />
disease: The Cooperative Crohn’s Disease Study in Sweden.<br />
Gastroenterology 1982;83:550-62.<br />
15. Colombel JF, Lémann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et<br />
<strong>al</strong>. A controlled tri<strong>al</strong> comparing ciprofloxacin with mes<strong>al</strong>amine for the treatment<br />
of active Crohn’s disease. Groupe d’Etudes Therapeutiques des<br />
affections Inflammatoires de Tube Digestif (GETAID). Am J Gastroentrol<br />
1999;94:674-8.<br />
16. Faubion WJ, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The<br />
natur<strong>al</strong> history of corticosteroid therapy for inflammatory bowel disease:<br />
a population-based study. Gastroenterology 2001;121:255-60.<br />
17. Loftus EV, Schoenfels P, Sandborn WJ. The epidemiology and natur<strong>al</strong> history<br />
of Crohn’s disease in population-based patient cohorts from North<br />
America: a systematic review. Aliment Pharmacol Ther 2002;16:51-60.<br />
18. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman<br />
J, et <strong>al</strong>. A short-term study of chimeric monoclon<strong>al</strong> antibody cA2 to<br />
tumour necrosis factor <strong>al</strong>pha for Crohn’s disease. N Engl J Med<br />
1997;337:1029-35.<br />
19. Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A,<br />
et <strong>al</strong>. Influence of immunogenicity on the long-term efficacy of infliximab<br />
in Crohn’s disease. N Engl J Med 2003;348:601-8.<br />
20. Simms l, Steinhart AH. Budesonide for maintenance of remission in<br />
Crohn’s disease (Cochrane Review).Cochrane Database Systems Review<br />
2001;I:CD002913.<br />
21. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for<br />
perine<strong>al</strong> Crohn’s disease: a follow-up study. Gastroenterology<br />
1982;83:383-7.<br />
22. Remicade. Ficha técnica. Centocor/Shering-Plough. 2004.<br />
23. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et<br />
<strong>al</strong>. A comparison of methotrexate with placebo for the maintenance of<br />
remission in Crohn’s disease. New Engl J Med 2000;342:1627-32.<br />
24. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled<br />
double blind study of azathioprine in the management of Crohn’s<br />
disease. Gut 1995;37:674-8.<br />
25. Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, et <strong>al</strong>.<br />
A randomized, double-blind, controlled withdraw<strong>al</strong> tri<strong>al</strong> in Crohn’s disease<br />
patients in long-term remission on azathioprine. Gastroenterology<br />
2005;128:1812-8.<br />
26. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter tri<strong>al</strong><br />
of 6-mercaptopurine and prednisone in children with newly diagnosed<br />
Crohn’s disease. Gastroenterology 2000;119:895-902.<br />
27. D’Haens GR, Baert F, Van Assche G, Caenepeel F, Vergauwe P, Tuynman<br />
H, et <strong>al</strong>. Better outcome with potent top-down induction therapy in<br />
recent onset Crohn’s disease. Gut 2005;54:A17.<br />
21 • Enfermedad Inflamatoria Intestin<strong>al</strong> <strong>al</strong> día - Vol. 5 - Nº. 1 - 2006
Change language